School Inner City Air Study
Part of paid clinical trials in Boston, Massachusetts.
- Sponsor
- Massachusetts General Hospital
- Study ID
- NCT05953233
- Status
- Recruiting
Conditions
- Viral Infection
Eligibility Criteria
- Sex
- ALL
- Age
- 6 Years - 90 Years
- Healthy Volunteers
- Accepted
Interventions
- Active classroom HEPA cleaner — OTHERCommercially available portable HEPA cleaner
- Sham classroom HEPA cleaner — OTHERCommercially available portable HEPA cleaner with filtration device removed
Study Details
The goal of this randomized clinical trial is to test the efficacy of high efficiency particulate air (HEPA) cleaners in reducing respiratory viral exposure and infections in elementary school classrooms. Classrooms will be randomized to active vs. sham HEPA cleaners. The main questions it aims to answer are: * Do classroom HEPA cleaners reduce exposure to viruses? * Do classroom HEPA cleaners reduce student and teacher infections? * Do classroom HEPA cleaners reduce infections in family members?
Key Dates
- Start date
- Sep 15, 2024
- Status verified
- Dec 2025
- Primary completion
- Aug 31, 2029
- Completion
- Aug 31, 2030
Study Design
- Enrollment
- 200 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- PREVENTION
Arms
- Experimental: Active HEPA cleanerActive HEPA cleaners will be placed in classrooms throughout the school year
- Placebo Comparator: Sham HEPA cleanerSham HEPA cleaners will be placed in classrooms throughout the school year
Primary Outcome Measure
Viral pathogen detected in upper respiratory sample [ Time Frame: 1 year ]
Central Contacts
- Peggy Lai, MD MPH617-875-9878
- Wanda Phipatanakul, MD MS857-218-5336
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Mass General Brigham | Boston | Massachusetts | 02114 | Peggy Lai, MD MPH |
Find similar trials in Boston, MA
By research site
Related Studies
- Donor-Derived Viral Specific T-cells (VSTs)PHASE1/PHASE2 · Recruiting · Children's Hospital Medical Center, Cincinnati · Akron, Ohio
- Third Party Viral Specific T-cells (VSTs)PHASE2 · Recruiting · Children's Hospital Medical Center, Cincinnati · Akron, Ohio
- Adoptive Cord Blood Immunotherapy for EBV, CMV, BKV and Adenovirus Reactivation/Infection or ProphylaxisPHASE1/PHASE2 · Recruiting · Catherine Bollard · Washington D.C., District of Columbia
- TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.PHASE1 · Recruiting · Baylor College of Medicine · Houston, Texas